Using Ga68-FAPI-46 PET/CT to assess peritoneal carcinomatosis before surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical imaging trial evaluates the effectiveness of Ga68-FAPI-46 PET/CT in accurately assessing peritoneal carcinomatosis in patients with colorectal and ovarian cancer. The study aims to correlate the imaging findings with intraoperative histopathology results to determine the accuracy of this novel radiotracer. Ga68-FAPI-46 targets fibroblast activation protein in the tumor microenvironment, potentially offering improved sensitivity over traditional imaging methods. Participants will undergo PET/CT scans prior to scheduled cytoreductive surgery.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically proven colorectal and ovarian cancer.
* Known or suspected peritoneal metastases from the tumour of origin.
* Scheduled for peritoneal complete cytoreductive surgery with curative intent with or without neoadjuvant chemotherapy.
* ECOG (Eastern Cooperative Oncology Group) Performance status ≤2.
* Signed written informed consent obtained before any study-specific screening procedures.

Exclusion Criteria:

* Non-resectable extra-abdominal metastasis and/or \>3 hepatic metastases on standard work-up
* Known chronic inflammatory conditions including the intestinal system (eg. inflammatory bowel disease, Crohn's disease)
* Pregnant and lactating women
* Previous or concurrent malignancy diagnosed within the last 3 years except adequately treated in situ carcinoma of the cervix uteri and basal or squamous cell skin cancer.
* Subjects with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study.

Where it's running

• Institut Jules Bordet
  Brussels, Belgium Recruiting

Study contacts

• Principal investigator: Patrick Flamen — Jules Bordet Institute
• Study coordinator: Loubna Taraji Schiltz
• Email: loubna.taraji@hubruxelles.be
• Phone: +32 (0) 2 541 37 81

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Repeated PIPAC plus standard platinum–taxane chemotherapy for advanced ovarian cancer with peritoneal spread

  This test sees if adding repeated cisplatin-based PIPAC to standard platinum–taxane chemotherapy helps women aged 18–75 with newly diagnosed FIGO IIIB–IIIC epithelial ovarian cancer and visible peritoneal carcinomatosis.

  Recruiting Phase 2 Moscow Regional Oncological Dispensary · Balashikha · NCT07514494

• Enhanced Recovery After Surgery for adults with peritoneal carcinomatosis undergoing cytoreductive surgery with or without HIPEC

  This project will try an Enhanced Recovery After Surgery (ERAS) program to see if it shortens hospital stays after cytoreductive surgery with or without HIPEC for adults with peritoneal carcinomatosis.

  Recruiting Fondazione del Piemonte per l'Oncologia · Candiolo, Turin and 1 other locations · NCT07493876

• PIPAC with Mitomycin C for unresectable peritoneal cancer

  This phase 1 study tests a breathy, pressurized chemotherapy method (PIPAC-MMC) to see if it is safe and tolerable for adults with unresectable peritoneal carcinomatosis from colorectal, appendiceal, or small bowel cancers.

  Recruiting Phase 1 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07487168

• Heated versus aerosolized chemotherapy delivered into the abdomen for cancer that has spread to the peritoneum

  This study will test whether heated (HIPEC) or aerosolized (PIPAC) mitomycin-based chemotherapy given into the abdomen works better and is safer for adults whose cancer has spread to the peritoneum.

  Recruiting Phase 2 Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania · NCT07282834

• Adding paclitaxel into the abdominal cavity for gastric cancer that has spread to the peritoneum

  This trial will try adding paclitaxel delivered directly into the abdomen to standard IV chemotherapy for people with gastric or gastroesophageal junction cancer that has spread to the lining of the abdominal cavity to see if it slows disease growth and helps them live longer.

  Recruiting at 78 sites Phase 2/3 Eastern Cooperative Oncology Group · Irvine, California and 77 other locations · NCT07001748

• Blood clearance of nucleosomes and CTCF after surgery for colorectal cancer with peritoneal spread

  This test will see if blood levels of nucleosomes and CTCF can indicate whether adults with colorectal cancer that has spread to the peritoneum have had all visible tumor removed by cytoreductive surgery.

  Recruiting Hospices Civils de Lyon · Pierre-Bénite · NCT06929013

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.